JNJ · News · 20261019N

TALVEY Label Expansion

JOHNSON & JOHNSON · 2026-10-19 · Importance 34 · Surprise 42

European regulators recommended expanding TALVEY’s use in relapsed or refractory multiple myeloma. The recommendation would add another oncology indication to Johnson & Johnson’s product portfolio if formally approved. The update concerns TALVEY, an oncology asset within the company’s Innovative Medicine business. The reported regulatory action was cited alongside Johnson & Johnson’s third-quarter earnings and dividend affirmation.